Özet:

Prostate specific antigen (PSA) is the most commonly used marker for prostate cancer. PSA-based screening has reduced disease-specific mortality. However, PSA is not specific for prostate cancer, but is specific for prostate tissue and increases in benign conditions. Material and Methods: In our study, 63 patients with PSA values of 1.5 ng / ml or less were evaluated retrospectively with 636 patients who underwent prostate sampling because of the suspicion of prostate cancer. Results: In our study, 34.9% prostate cancer and 4.1% ASAP were detected below 1.5 ng / ml of PSA. Our results suggest that a significant number of cancers were detected below 1.5 ng / ml of PSA. A significant number of prostate cancers are found below 1.5 ng / ml of PSA. The lack of a PSA value that we can say without prostate cancer leads to the need for a low cost and reliable marker.